<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103865</url>
  </required_header>
  <id_info>
    <org_study_id>AAT S&amp;A</org_study_id>
    <nct_id>NCT05103865</nct_id>
  </id_info>
  <brief_title>Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions</brief_title>
  <official_title>Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Monfort Montolio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardenal Herrera University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown&#xD;
      positive results in the treatment of various pathologies. This study assesses the viability&#xD;
      of the implementation and the efectiveness of an AAT program in patients diagnosed with&#xD;
      substance abuse disorder and associated mental disorders (dual pathology).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Animal assisted therapy (AAT) is a complementary intervention to therapy that presents&#xD;
      positive results in the treatment of different pathologies. The study assesses the&#xD;
      implementation and effectiveness of a TAA program in patients diagnosed with substance use&#xD;
      disorder and schizophrenia spectrum disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2015</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Life Skills Profile questionnaire (LSP)</measure>
    <time_frame>Change from Life Skills at 3-6-9 months (12 minutes)</time_frame>
    <description>This questionnaire evaluates aspects of functioning that affect daily activities and the adaptation of people with mental illnesses in the community. It contains 39 items that are grouped into self-care, social-interpersonal behaviour, communication-social contact, non-personal social behaviour and autonomous life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barrat impulsiveness scale (BIS-11)</measure>
    <time_frame>Change from impulsiveness at 3-6-9 months (12 minutes)</time_frame>
    <description>This instrument is composed of 30 items distributed into three sub-scales: nonplanning, motor and attentional. The total impulsiveness score was also obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calgary Depresión Scale for Schizophrenia (CDSS)</measure>
    <time_frame>Change from Depresión at 3-6-9 months (12 minutes)</time_frame>
    <description>El cuestionario es un intrumento estructurado, adminisitrado por un clínico de forma heteroaplicada para población adulta, con un tiempo aproximado de administración de entre 10 y 30 minutos, y aborada el área terapéutica relativa a la sintomatología de los trastornos depresivos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosenberg Self-Esteem Scale</measure>
    <time_frame>Change from self.-esteem at 3-6-9 months (12 minutes)</time_frame>
    <description>The questionnaire consists of 10 statements of the feelings that the person has about himself. Five of the statements are addressed positively (items 1, 2, 4, 6 and 7) and 5 negatively (items 3, 5, 8, 9 and 10).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and negative symptom scale (PANSS)</measure>
    <time_frame>Change from Positive and negative symptom at 3-6-9 months (12 minutes)</time_frame>
    <description>It is a semi-structured and hetero-applied questionnaire for the adult population. The application time is between 30-60 minutes and evaluates the positive and negative symptoms of schizophrenia and other psychotic disorders.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Diagnosis, Dual (Psychiatry)</condition>
  <arm_group>
    <arm_group_label>Experimental group (EG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Animal-assisted therapy (AAT)</intervention_name>
    <arm_group_label>Experimental group (EG)</arm_group_label>
    <other_name>ATT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual treatment</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-5 criteria for substance abuse disorder and the presence of schizophrenia&#xD;
&#xD;
          -  Voluntary participant in the study and having signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose functioning could be altered by factors not specifically related to&#xD;
             addictive pathology or mental disorder (severe cognitive impairment, intellectual&#xD;
             deficiency or language barrier)&#xD;
&#xD;
          -  Animal-specific phobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cardenal Herrera University</investigator_affiliation>
    <investigator_full_name>Miguel Monfort Montolio</investigator_full_name>
    <investigator_title>Sponsor-investigator</investigator_title>
  </responsible_party>
  <keyword>Animal-assisted therapy</keyword>
  <keyword>everyday life skills</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>residential treatment</keyword>
  <keyword>dual pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

